lobbying_activities: 2784512

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2784512	7a536919-5a25-4dfe-8ec8-a8ef54f113db	Q1	RED+BLUE STRATEGIES	400693064	COHERUS BIOSCIENCES	2022	first_quarter	PHA	S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.	HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2022-04-19T13:04:58-04:00